Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors

References

• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227-42. doi:10.1038/nri3405. PMID:23470321
   PubMed Web of Science ®Google Scholar
• Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457-72. doi:10.1038/nrc3973. PMID:26205340
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432-3. doi:10.1126/science.342.6165.1432. PMID:24357284
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3(1):e27297. doi:10.4161/onci.27297. PMID:24701370
   PubMed Web of Science ®Google Scholar
• Callahan MK, Postow MA, Wolchok JD. Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016;44(5):1069-78. doi:10.1016/j.immuni.2016.04.023. PMID:27192570
   PubMed Web of Science ®Google Scholar
• Müller D. Antibody fusions with immunomodulatory proteins for cancer therapy. Pharmacol Ther. 2015;154:57-66. doi:10.1016/j.pharmthera.2015.07.001. PMID:26145167
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61-73. doi:10.1016/j.immuni.2013.07.005. PMID:23890064
   PubMed Web of Science ®Google Scholar
• Wu AA, Drake V, Huang HS, Chiu S, Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology. 2015;4(7):e1016700. doi:10.1080/2162402X.2015.1016700. PMID:26140242
   PubMed Web of Science ®Google Scholar
• Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov. 2013;12(2):147-68. doi:10.1038/nrd3930. PMID:23334208
   PubMed Web of Science ®Google Scholar
• Hornig N, Kermer V, Frey K, Diebolder P, Kontermann RE, Müller D. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. J Immunother. 2012;35(5):418-29. doi:10.1097/CJI.0b013e3182594387. PMID:22576347
   PubMed Web of Science ®Google Scholar
• Hornig N, Reinhardt K, Kermer V, Kontermann RE, Müller D. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. Cancer Immunol Immunother. 2013;62(8):1369-80. doi:10.1007/s00262-013-1441-7. PMID:23715927
   PubMed Web of Science ®Google Scholar
• Li G, Wu X, Zhang F, Li X, Sun B, Yu Y, Yin A, Deng L, Yin J, Wang X. Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137(4):695-703. doi:10.1007/s00432-010-0905-9. PMID:20563597
   PubMed Web of Science ®Google Scholar
• Gray JC, French RR, James S, Al-Shamkhani A, Johnson PW, Glennie MJ. Optimising anti-tumour CD8T-cell responses using combinations of immunomodulatory antibodies. Eur J Immunol. 2008;38(9):2499-511. doi:10.1002/eji.200838208. PMID:18792403
   PubMed Web of Science ®Google Scholar
• Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgström P, Lustgarten J. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer. 2005;116(6):934-43. doi:10.1002/ijc.21098. PMID:15856473
   PubMed Web of Science ®Google Scholar
• Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654-66. doi:10.1056/NEJMoa051424. PMID:16371631
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-4. doi:10.1126/science.1129139. PMID:17008531
   PubMed Web of Science ®Google Scholar
• Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944-51. doi:10.1200/JCO.2008.19.6147. PMID:19858404
   PubMed Web of Science ®Google Scholar
• De la Cruz-Merino L, Henao Carrasco F, Vicente Baz D, Nogales Fernández E, Reina Zoilo JJ, Codes Manuel de Villena M, Pulido EG. Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. Clin Dev Immunol. 2011;2011:174149. doi:10.1155/2011/174149. PMID:22162710
   PubMedGoogle Scholar
• Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14(1):24-35. doi:10.1038/nri3567. PMID:24336101
   PubMed Web of Science ®Google Scholar
• Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res. 2009;69(21):8412-9. doi:10.1158/0008-5472.CAN-09-0852. PMID:19843860
   PubMed Web of Science ®Google Scholar
• Dobrzanski MJ. Expanding roles for CD4T cells and their subpopulations in tumor immunity and therapy. Front Oncol. 2013;3:63. doi:10.3389/fonc.2013.00063. PMID:23533029
   PubMedGoogle Scholar
• Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM, Avogadri-Connors F, Yuan J, Li Y, et al. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med. 2012;209(11):2113-26. doi:10.1084/jem.20120532. PMID:23008334
   PubMed Web of Science ®Google Scholar
• Qui HZ, Hagymasi AT, Bandyopadhyay S, St Rose MC, Ramanarasimhaiah R, Ménoret A, Mittler RS, Gordon SM, Reiner SL, Vella AT, et al. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4T cells to program cytotoxic Th1 differentiation. J Immunol. 2011;187(7):3555-64. doi:10.4049/jimmunol.1101244. PMID:21880986
   PubMed Web of Science ®Google Scholar
• Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43(8):1129-43. doi:10.1016/j.molimm.2005.07.034. PMID:16139892
   PubMed Web of Science ®Google Scholar
• Hornig N. Combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy [dissertation]. Stuttgart (Germany): University of Stuttgart; 2013.
   Google Scholar
• Kischel R, Hausmann S, Klinger M, Baeuerle PA, Kufer P. Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110. Poster presented at: AACR Annual Meeting; 2009 April; Denver, USA.
   Google Scholar
• Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res. 2003;63(10):2546-52. PMID:12750278
   PubMed Web of Science ®Google Scholar
• Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 2012;1(4):458-66. doi:10.4161/onci.19855. PMID:22754764
   PubMed Web of Science ®Google Scholar
• Joss A, Akdis M, Faith A, Blaser K, Akdis CA. IL-10 directly acts on T cells by specifically altering the CD28co-stimulation pathway. Eur J Immunol. 2000;30(6):1683-90. doi:10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A. PMID:10898505
   PubMed Web of Science ®Google Scholar
• Kim YJ, Broxmeyer HE. Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells. J Hematother Stem Cell Res. 2001;10(4):441-9. doi:10.1089/15258160152509064. PMID:11522228
   PubMedGoogle Scholar
• Kim YJ, Stringfield TM, Chen Y, Broxmeyer HE. Modulation of cord blood CD8+ T-cell effector differentiation by TGF-beta1 and 4-1BB costimulation. Blood. 2005;105(1):274-81. doi:10.1182/blood-2003-12-4343. PMID:15353478
   PubMed Web of Science ®Google Scholar
• Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ. PLoS One. 2012;7(8):e42459. doi:10.1371/journal.pone.0042459. PMID:22870329
   PubMed Web of Science ®Google Scholar
• Kim YJ, Han MK, Broxmeyer HE. 4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells. Blood. 2008;111(3):1378-86. doi:10.1182/blood-2007-01-069450. PMID:18024793
   PubMed Web of Science ®Google Scholar
• Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin Cancer Res. 2012;18(17):4514-21. doi:10.1158/1078-0432.CCR-11-3224. PMID:22711703
   PubMed Web of Science ®Google Scholar
• Garrison K, Hahn T, Lee WC, Ling LE, Weinberg AD, Akporiaye ET. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother. 2012;61(4):511-21. doi:10.1007/s00262-011-1119-y. PMID:21971588
   PubMed Web of Science ®Google Scholar
• Triplett TA, Tucker CG, Triplett KC, Alderman Z, Sun L, Ling LE, Akporiaye ET, Weinberg AD. STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade. Cancer Immunol Res. 2015;3(5):526-35. doi:10.1158/2326-6066.CIR-14-0187. PMID:25627655
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016;37(3):193-207. doi:10.1016/j.it.2016.01.002. PMID:26839260
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2014;3(10):e957994. doi:10.4161/21624011.2014.957994. PMID:25941578
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428-1433. doi:10.1126/science.aaf1292. PMID:28280247
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, et al. Rescue of exhausted CD8T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355(6332):1423-1427. doi:10.1126/science.aaf0683. PMID:28280249
   PubMed Web of Science ®Google Scholar
• Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol. 2013;191(5):2829-36. doi:10.4049/jimmunol.1202777. PMID:23918985
   PubMed Web of Science ®Google Scholar
• Chen S, Lee LF, Fisher TS, Jessen B, Elliott M, Evering W, Logronio K, Tu GH, Tsaparikos K, Li X, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8T cells in a poorly immunogenic tumor model. Cancer Immunol Res. 2014;3(2):149-60. doi:10.1158/2326-6066.CIR-14-0118. PMID:25387892
   PubMed Web of Science ®Google Scholar
• Azpilikueta A, Agorreta J, Labiano S, Pérez-Gracia JL, Sánchez-Paulete AR, Aznar MA, Ajona D, Gil-Bazo I, Larrayoz M, Teijeira A, et al. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. J Thorac Oncol. 2016;11(4):524-36. doi:10.1016/j.jtho.2016.01.013. PMID:26845193
   PubMed Web of Science ®Google Scholar
• Kocak E, Lute K, Chang X, May KF Jr, Exten KR, Zhang H, Abdessalam SF, Lehman AM, Jarjoura D, Zheng P, et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 2006;66(14):7276-84. doi:10.1158/0008-5472.CAN-05-2128. PMID:16849577
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017;5:16. doi:10.1186/s40425-017-0218-5. PMID:28239469
   PubMed Web of Science ®Google Scholar
• Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12(3):191-200. PMID:22343568
   PubMed Web of Science ®Google Scholar